Berenberg Bank Reiterates Buy Rating for AstraZeneca (LON:AZN)

Berenberg Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Monday morning, MarketBeat Ratings reports. They currently have a GBX 140 ($1.73) target price on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on the company. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. JPMorgan Chase & Co. restated an “overweight” rating and set a £140 ($173.05) target price on shares of AstraZeneca in a report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of GBX 7,935.67 ($98.09).

AstraZeneca Price Performance

Shares of LON AZN opened at £107.54 ($132.93) on Monday. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The business has a 50-day moving average of £104.96 and a 200-day moving average of £116.70. The stock has a market capitalization of £166.69 billion, a price-to-earnings ratio of 3,413.97, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a fifty-two week low of GBX 9,461 ($116.95) and a fifty-two week high of £133.88 ($165.49).

Insider Activity at AstraZeneca

In other news, insider Pascal Soriot bought 20,000 shares of the stock in a transaction dated Thursday, November 14th. The shares were bought at an average price of £102.03 ($126.12) per share, for a total transaction of £2,040,600 ($2,522,373.30). Also, insider Tony Mok purchased 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of £126.80 ($156.74) per share, with a total value of £190,200 ($235,105.07). 0.04% of the stock is owned by company insiders.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.